Company facts: Rhone-Poulenc

Article Abstract:

Rhone-Poulenc ranks first among chemicals companies in France, and has moved into healthcare, away from cyclical chemicals activities. The company has not many basic chemicals activities so has not benefited from a rise in the price of chemicals, while input prices have risen. Rhone-Poulenc's subsidiary, Rhone-Poulenc Rorer, has made a bid for Fisons which would create a strong group in the rapidly growing market for respiratory treatments. Margins should be helped by an easing of prices of commodity chemicals.

Management

---

Hoechst aims for spin-off

Article Abstract:

Hoechst aims to spin off its pharmaceuticals businesses by 2000, according to Jurgen Dormann, chief executive. The company ranks second in the world drugs market in terms of sales. A spin-off could lead to a re-rating of the group's shares, since investors tend to give a higher rating to such shares when they are hived off into a separate company. Bayer could carry out a similar move in order to enhance its share value. The alliance between Sandoz and Ciba means that restructuring is more likely to occur.

Mergers, acquisitions and divestments, Hoechst AG

---

Rhone sounds early warning

Article Abstract:

Rhone Poulenc has stated that results for 1995 will be lower than anticipated. The company's 1995 profit is scheduled for release by Jan 31 1996. External factors such as strikes among public sector employees in France and slower economic growth have affected results, but there is also concern over provisions. A JV has been set up with Hoechst which will operate in the US and will produce plasma and blood products for transplants and hemophilia treatments.

Biological Product (except Diagnostic) Manufacturing, Biological products exc. diagnostic, Blood Plasma & Products, Finance

Similar abstracts:

• Abstracts: Company facts: Roche. Roche: mixed week. Company facts: Merck
• Abstracts: Get out of accounts that gather dust. Investing for income: all roads carry risk. Long wait for Midshires money
• Abstracts: British Assets Trust: dubious asset. Kleinwort trust cash escape. Kleinwort European Privatisation Trust: Euro vision
• Abstracts: Flea collars and peat held back profits. Amberley. Animal house

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.